Aliskiren

Aliskiren
IUPAC ime
	(2S,4S,5S,7S)-5-amino-N-(2-karbamoil-2,2-dimetiletil)-4-hidroksi-7[4-metoksi-3-(3-metoksipropoksi)fenil]metil8-metil-2-(propan-2-il)nonanamid
Klinički podaci
Drugs.com	Monografija
MedlinePlus	a607039
Podaci o licenci	EU EMA: Rasilez; US FDA: Tekturna;
Kategorija trudnoće	C in first trimester; D in second and third trimesters;
Način primene	PO (oralno)
Pravni status
Pravni status	UK: POM (Samo na recepat) ; US: ℞-only ;
Farmakokinetički podaci
Bioraspoloživost	niska (oko 2,5%)
Metabolizam	Hepatički, CYP3A4-posredovano
Poluvreme eliminacije	24 sata
Izlučivanje	Renalno
Identifikatori
CAS broj	173334-57-1
ATC kod	C09XA02 (WHO) ; C09XA52 (sa HCT)
PubChem	CID 5493444
DrugBank	DB01258
ChemSpider	4591452
UNII	502FWN4Q32
KEGG	D03208
ChEBI	CHEBI:601027
ChEMBL	CHEMBL1639
Hemijski podaci
Formula	C30H53N3O6
Molarna masa	551,758 g/mol
	SMILES O=C(N)C(C)(C)CNC(=O)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1; ;
	InChI InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1 ; Key:UXOWGYHJODZGMF-QORCZRPOSA-N ;

Aliskiren (Tekturna (SAD); Rasilez (UK i druge zemlje)) prvi je u klasi lekova koji se nazivaju direktnim reninskim inhibitorima. Njegova trenutna licencirana indikacija je primarna hipertenzija.

Aliskiren su razvila preduzeća Novartis i Speedel.^[1]^[2] On je odobren u SAD 2007. za tretman primarne hipertenzije.

Osobine

Osobina	Vrednost
Broj akceptora vodonika	7
Broj donora vodonika	4
Broj rotacionih veza	19
Particioni koeficijent^[3] (ALogP)	3,3
Rastvorljivost^[4] (logS, log(mol/L))	-7,5
Polarna površina^[5] (PSA, Å²)	146,1

Reference

^ Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M (2005). „Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients”. Circulation. 111 (8): 1012—8. PMID 15723979. doi:10.1161/01.CIR.0000156466.02908.ED.
^ Straessen JA, Li Y, Richart T (2006). „Oral Renin Inhibitors”. Lancet. 368 (9545): 1449—56. PMID 17055947. doi:10.1016/S0140-6736(06)69442-7.
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Spoljašnje veze

Prescribing Information for Tekturna
aliskiren на US National Library of Medicine Medical Subject Headings (MeSH)
Chemical synthesis

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M (2005). „Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients”. Circulation. 111 (8): 1012—8. PMID 15723979. doi:10.1161/01.CIR.0000156466.02908.ED.

[2] Straessen JA, Li Y, Richart T (2006). „Oral Renin Inhibitors”. Lancet. 368 (9545): 1449—56. PMID 17055947. doi:10.1016/S0140-6736(06)69442-7.

[3] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[4] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[5] Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]